Category: Devyn Smith

  • CRISPR-editing biotech Arbor Bio adds $215M for liver, CNS disease therapies

    Arbor Biotechnologies raised new cash to keep up the pace in the chase for new genetic medicines. The MIT spinout applies artificial intelligence and machine learning to discover CRISPR enzymes applicable for gene-editing therapies; the Series B financing comes as programs in liver and central nervous system disorders move closer to human testing.